![](/content/dam/SHC/doctors-medicalstaff/r/riaz-fauzia.jpg/_jcr_content/renditions/original.transform/280x280-q76/image.jpg)
![Fauzia Riaz, M.D., M.H.S.](/content/dam/SHC/doctors-medicalstaff/r/riaz-fauzia.jpg/_jcr_content/renditions/original.transform/280x280-q76/image.jpg)
Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2019)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2015)
- Fellowship: Yale Cancer Center (2019) CT
- Chief Residency, Georgetown University Medical Center, DC (2016)
- Residency: Georgetown University Medical Center (2016) DC
- Medical Education: University of South Florida Morsani College of Medicine (2012) FL
Memberships
- Panel Member, National Comprehensive Cancer Network--Hematopoietic Growth Factors Panel (2020 - Present)
Publications
-
Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer
Riaz, F., Presley, C. J., Chiang, A. C., Longtine, J. A., Soulos, P. R., Adelson, K. B., … Gross, C. P. (2019). Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. JOURNAL OF GERIATRIC ONCOLOGY, 10(4), 669–72. -
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., … Gross, C. P. (2020). Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice, OP2000010. -
The adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., … Gross, C. P. (2020). The adoption of immune checkpoint inhibitors and patterns of care at the end of life. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
Parikh, R. B., Cohen, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., … Mamtani, R. (2020). Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
Parikh, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., Cohen, R. B., … Mamtani, R. (2021). Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. JAMA Oncology. -
Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.
Parikh, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., Cohen, R. B., … Mamtani, R. (2021). Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Practice Locations
Breast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CABreast Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Women's Cancer Center Palo Alto, CA
Palo Alto, CAStanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(57 reviews)
View More
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records